Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ganciclovir
Drug ID BADD_D01003
Description An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
Indications and Usage For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients.
Marketing Status approved; investigational
ATC Code J05AB06; S01AD09
DrugBank ID DB01004
KEGG ID D00333
MeSH ID D015774
PubChem ID 135398740
TTD Drug ID D05ARP
NDC Product Code 12806-6941; 51754-2500; 12869-803; 59651-108; 24208-535; 42023-173
UNII P9G3CKZ4P5
Synonyms Ganciclovir | Gancyclovir | BW-759 | Ganciclovir Sodium | Ganciclovir, Monosodium Salt | RS-21592 | BIOLF-62 | Cytovene
Chemical Information
Molecular Formula C9H13N5O4
CAS Registry Number 82410-32-0
SMILES C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nuchal rigidity17.05.02.006; 15.05.04.005--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Ischaemia24.04.02.004--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Spinal cord disorder17.10.01.010--Not Available
Decreased appetite08.01.09.028; 14.03.01.005--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Psychotic disorder19.03.01.002--
Hepatobiliary disease09.01.08.003--Not Available
Renal impairment20.01.03.010--Not Available
Device related infection11.01.08.018; 08.07.01.005--
Procedural pain12.02.05.007; 08.01.08.009--Not Available
Bone marrow failure01.03.03.005--
Acute kidney injury20.01.03.016--
Device related sepsis11.01.11.008; 08.07.01.004--Not Available
Pneumocystis jirovecii pneumonia22.07.08.009; 11.03.07.005--Not Available
Multiple organ dysfunction syndrome08.01.03.057--
Anal incontinence17.05.01.021; 07.01.06.029--
Attention deficit hyperactivity disorder19.21.04.004--Not Available
Fixed eruption23.03.05.008; 10.01.01.037; 08.01.06.025--Not Available
Mucosal disorder08.01.06.029--Not Available
The 9th Page    First    Pre   9    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene